BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
August 05, 2020 at 07:01 am EDT
Share
CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress, taking place on September 18-22, 2020.
Mini Oral Presentations:
Title:
Clinical Benefit in Biomarker-Positive Patients (pts) with Locally Advanced or Metastatic Solid Tumors Treated with the PARP1/2 Inhibitor Pamiparib in Combination with Low-Dose (LD) Temozolomide (TMZ)
Mini Oral #:
530MO
Session Title:
Developmental Therapeutics
Presenter:
Agostina Stradella, M.D. Catalan Institute of Oncology, Spain
Title:
BGB-A333, an Anti-PD-L1 Monoclonal Antibody, in Combination with Tislelizumab in Patients with Urothelial Carcinoma
Mini Oral #:
535MO
Session Title:
Developmental Therapeutics
Presenter:
Juan Martin-Liberal, M.D., Ph.D., Catalan Institute of Oncology, Spain
Poster Presentations:
Title:
Phase 2 Study of Pamiparib in Chinese Patients (pts) with Advanced Ovarian Cancer (aOC)
Poster #:
820P
Session Title:
Poster Display
Lead Author:
Xiaohua Wu, M.D., Ph.D., Fudan University Shanghai Cancer Center, China
Title:
Safety and Efficacy of Long-term Exposure (LTE) to Tislelizumab in Chinese Patients with Advanced Solid Tumors
Poster #:
522P
Session Title:
Poster Display
Lead Author:
Lin Shen, M.D., Ph.D., Peking University Cancer Hospital & Institute , China
Title:
Tislelizumab + Chemotherapy vs Chemotherapy Alone as First-line Treatment for Locally Advanced/Metastatic Nonsquamous NSCLC
Poster #:
1263P
Session Title:
Poster Display
Lead Author:
Shun Lu, M.D., Shanghai Chest Hospital, China
Title:
Updated Analysis of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (SQ NSCLC)
Poster #:
1264P
Session Title:
Poster Display
Lead Author:
Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, China
Title:
Investigation of PD-L1 Expression and Tislelizumab Efficacy in Gastroesophageal Adenocarcinoma Using a Novel Tumor and Immune Cell Score with VENTANA PD-L1 (SP263) Assay and Combined Positive Score (CPS)
Poster #:
154P
Session Title:
Poster Display
Lead Author:
Yee Chao, Ph.D., Taipei Veterans General Hospital, Taiwan
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,100+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.